AAV delivery of the CRISPR/Cas9 system or therapeutic genes has been proven very successful for the treatment of retinal diseases in various preclinical studies.43, 44, 45 To restrict the expression of SpCas9 to photoreceptors, we employed the interphotoreceptor retinoid-binding protein (IRBP) promoter, while GFP expression, driven by the RHO promoter, tracked the expression of gRNAs in injected eyes. The gene discussed is RHO; the disease is Abnormal retinal morphology.